相关实验视频

Updated: Jan 11, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

在患有败血性休克的患者中,输血压素启动的时间:更新的系统性审查和分析与试验序列分析

Anirban Bhattacharjee¹, Priyankar K Datta², Vivek Kumar³

¹Department of Anaesthesiology, Critical Care and Pain Medicine, All India Institute of Medical Sciences, Guwahati, Assam, India.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine

|November 10, 2025

概括

在败血性休克患者中早期开始使用血管压素可以显著降低短期死亡率并改善结果. 这一系统性审查强调了在重症监护中及时施用血压素的好处.

科学领域:

关键护理医学关键护理医学
药理学药理学是指药理学的学科.
系统性审查和元分析

背景情况:

败血性休克是一种危及生命的疾病,需要及时干预.
血管压素是用于治疗败血症休克的关键血管压缩剂.
开始输血压素的最佳时间仍然是一个关键的临床问题.

研究的目的:

系统地审查和元分析血管压素启动时间.
评估早期 (<6小时) 与晚期 (>6小时) 血管压素启动和以患者为中心的结局在败血性休克中之间的关联.
为了评估对死亡率,替代疗法,心律失常和停留时间的影响.

主要方法:

在Embase,PubMed和Web of Science数据库中进行系统搜索.
包括从2013年1月到2024年12月的前性,后性研究和RCT.
七项涉及3,993名患有败血性休克的成年患者的研究的元分析.

主要成果:

早期开始使用血管压素与显著降低短期死亡率有关 (RR 0.84,p=0.033).
减少了医院死亡率 (RR 0.83,p=0.0003),减少了对置换疗法的需要 (RR 0.78,p=0.043),以及更短的医院LOS (MD -1.83天,p=0.02).
在新发作的心律失常或ICU停留时间方面没有发现显著差异.

结论:

在六个小时内开始服用血管压素,为败血症休克患者提供了显著的生存优势.
尽管有好处,但所包含的研究具有高偏差风险,因此需要谨慎解释.
需要进一步的高质量研究来证实这些发现.

关键词:

进行元分析分析.死亡率死亡率死亡率败血症的冲击是一个令人震惊的结果.调节时间的时间.血管压力中的压力.

更多相关视频

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

Echocardiographic Assessment Using Subxiphoid-Only Examination for Hypotensive Patients

Echocardiographic Assessment Using Subxiphoid-Only Examination for Hypotensive Patients

Published on: April 18, 2025

相关概念视频

Cardiopulmonary Resuscitation IV: Pharmacological Management

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...